An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Catalent, Inc. to Present at the Stephens Annual Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Catalent, Inc. (NYSE: CTLT), a leader in pharmaceutical and biotech solutions, announced participation in the Stephens Annual Investment Conference on November 16, 2022, at 11:00 a.m. ET. The event will feature members of the executive leadership team and will be accessible via a live webcast at investor.catalent.com. Catalent specializes in optimizing product development and supply for personalized medicines and new pharmaceuticals, with over 150 products launched annually, and nearly $5 billion in revenue in the 2022 fiscal year.
Positive
None.
Negative
None.
SOMERSET, N.J.--(BUSINESS WIRE)--
Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will participate at the Stephens Annual Investment Conference on November 16, 2022 at 11:00 a.m. ET.
A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.
About Catalent Catalent is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $5 billion in revenue in its 2022 fiscal year. For more information, visit www.catalent.com.
